Trial
NCT05378763
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
Phase IIISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Spectrum Pharmaceuticals, Inc
Collaborators
—
Condition
NSCLC
Intervention
Poziotinib
Why stopped
The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-24